Axial functionalisation of photoactive diazido platinum(iv) anticancer complexes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chemical reviews · 2025
   Review
2. Protonation of Pt(IV) Anticancer Complexes Assayed by Vibrational Ion Spectroscopy.ChemPlusChem · 2025
   Article
3. Leading prodrug strategies for targeted and specific release.Future medicinal chemistry · 2025
   Article
4. Light-Controlled Anticancer Activity and Cellular Uptake of a Photoswitchable Cisplatin Analogue.Journal of medicinal chemistry · 2024
   Article
5. Leveraging the Photofunctions of Transition Metal Complexes for the Design of Innovative Phototherapeutics.Small methods · 2024
   Review
6. Nanomaterials-Induced Redox Imbalance: Challenged and Opportunities for Nanomaterials in Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
   Review
7. Tuning the photoactivated anticancer activity of Pt(iv) compoundsChemical science · 2024
   Article
8. Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth-An Investigation of the Activation Mechanism and Their Nanoformulation.Pharmaceutics · 2024
   Article
9. New Tin (IV) and Organotin (IV) Complexes with a Hybrid Thiosemicarbazone/Hydrazone Ligand: Synthesis, Crystal Structure, and Antiproliferative Activity.Bioinorganic chemistry and applications · 2024
   Article
10. Radiometal-Labeled Photoactivatable Pt(IV) Anticancer Complex for Theranostic Phototherapy.Inorganic chemistry · 2023
    Article
11. Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs.Molecules (Basel, Switzerland) · 2023
    Review
12. A platinum-ruthenium hybrid prodrug with multi-enzymatic activities for chemo-catalytic therapy of hypoxic tumors.Chemical science · 2022
    Article
13. Photocytotoxicity and photoinduced phosphine ligand exchange in a Ru(ii) polypyridyl complex.Chemical science · 2022
    Article
14. Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs.Frontiers in chemistry · 2022
    Review
15. Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy.Frontiers in pharmacology · 2022
    Review
16. Single-Cell Chemistry of Photoactivatable Platinum Anticancer Complexes.Journal of the American Chemical Society · 2021
    Article
17. Platinum(IV)-azido monocarboxylato complexes are photocytotoxic under irradiation with visible light.Dalton transactions (Cambridge, England : 2003) · 2021
    Article
18. Facile protein conjugation of platinum for light-activated cytotoxic payload release.Chemical communications (Cambridge, England) · 2021
    Article
19. Metallodrugs are unique: opportunities and challenges of discovery and development.Chemical science · 2020
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

Abstract